Last reviewed · How we verify
Investigational drug
Unable to determine specific mechanism without drug name or code identifier.
At a glance
| Generic name | Investigational drug |
|---|---|
| Also known as | IFALMIN (standardized extract from channa micropeltes) |
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
This entry refers to an investigational drug from Pfizer in Phase 3 development, but without a specific drug name, brand name, or development code, the molecular mechanism cannot be accurately identified. Additional identifying information is required to characterize the drug's mechanism of action.
Approved indications
Common side effects
Key clinical trials
- TILs Plus Third-Generation EGFR-TKI Therapy for TKI-Resistant NSCLC (EARLY_PHASE1)
- Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia (PHASE2)
- A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (PHASE1)
- Study of TGM-312-SC01 in Healthy Participants and Adults With MASH (PHASE1, PHASE2)
- Clinical Evaluation of an Experimental Remineralization Product (NA)
- MK-7075 (Miransertib) in Proteus Syndrome (PHASE2)
- Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment (PHASE1, PHASE2)
- Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Investigational drug CI brief — competitive landscape report
- Investigational drug updates RSS · CI watch RSS
- Pfizer portfolio CI